Journal of Clinical Oncology
Articles in this Issue
G-DISCO: Gemcitabine-docetaxel intravesical instillation synchronous co-administration—A phase I study.
TPS897 Background: Treatment options are notably limited for BCG-unresponsive high-risk non-muscle invasive bladder cancer...
Evaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy.
877 Background: Occult pathological lymph node involvement at radical cystectomy (RC) in patients with clinical (cN0) bladder cancer (BC) remains a diagno...
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.
140 Background: In the phase II EXTEND iADT omPC basket, MDT+iADT improved progression-free survival (PFS) vs iADT. Here we present the primary results of...
Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: A comparative analysis with axitinib combined with standard-dose toripalimab.
532 Background: Oligometastatic renal cell carcinoma (RCC) involves limited metastases (1-5) and lies between localized and metastatic disease, with lower...
Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours.
636 Background: Testicular germ cell tumours (GCT) are the most common malignancy in young men, mainly in their 30s. While multimodal treatment leads to e...
Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer.
380 Background: Node-positive prostate cancer (PCa) poses a unique treatment challenge since bowel radiation tolerance often limits the delivery of doses...
Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
494 Background: Immuno-oncology (IO)-based combination therapy with or without anti-vascular endothelial growth factor (VE) has become a standard of care...
External validation of previously reported prognostic classifications for patients treated with second-line axitinib after immuno-oncology combination therapy for advanced renal cell carcinoma: JUOG retrospective study.
482 Background: To validate the prognostic classifications previously reported for patients with advanced renal cell carcinoma who received second-line ax...
Real-world outcomes in metastatic prostate cancer patients with ctDNA-detected <i>SPOP</i> mutations.
110 Background: Comprehensive genomic profiling (CGP) is recommended for patients (pts) with metastatic prostate cancer (mPC) to inform therapy. ctDNA ana...
Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer.
TPS274 Background: Prostate cancer remains the most common malignancy among men and the fifth leading cause of cancer-related mortality globally. Over the...
Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).
444 Background: Phase II data from the CALYPSO study (NCT02819596) has shown activity for durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D...
Renal cell carcinoma in kidney transplant recipients receiving immunosuppression: A 55-year retrospective single-center study.
599 Background: Immunosuppression, the key post-transplant therapy to prevent organ rejection, is associated with an increased cancer risk. Kidney transpl...
The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC).
445 Background: The treatment landscape of mRCC has evolved in recent years with the advent of immune-checkpoint inhibitors (ICIs). The Area Deprivation I...
Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.
167 Background: Addition of docetaxel (D) to ADT has demonstrated improved overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC)....
Characterization of genitourinary drug approvals by the FDA, 2020-2024.
872 Background: There were 255 cancer drug approvals by the US Food and Drug Administration (FDA) between January 2020 and October 2024. Although genitour...
Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).
583 Background: ChRCC is a rare form of kidney cancer that has shown limited response to immune checkpoint inhibitors currently used as the standard-of-ca...
Prospective analysis of AR-V7 expression in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) sequentially treated with docetaxel and enzalutamide.
250 Background: Androgen receptor splice variant 7 (AR-V7) has been associated with poor outcomes in mCRPC patients treated with androgen receptor pathway...
The impact of micropapillary histology and clinical staging on overall survival in bladder cancer: A retrospective analysis.
744 Background: Micropapillary variant bladder cancer (MPC) is a rare subtype of urothelial carcinoma, representing 0.01–2.2% of cases, with a higher stag...
Incidence and mortality trends in genitourinary cancer in Southeast Asia from 1990-2021.
619 Background: The global burden of genitourinary (GU) cancers has been increasing due to aging populations and advancements in technology. However, litt...
Clinical outcomes of lutetium-177-vipivotide tetraxetan in men with metastatic castration-resistant prostate cancer at a single academic center.
84 Background: Lutetium-177-vipivotide tetraxetan ( 177 Lu) was approved in 2022 for PSMA-positive metastatic castration-resistant...
<i>g</i> -Rate–based machine learning model to predict overall survival (OS) in patients with metastatic prostate cancer (mPC) while on treatment.
242 Background: Dynamic biomarkers to predict OS while a pt is on treatment are unavailable in mPC. We have developed g -rate meth...
Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial.
572 Background: Anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors and checkpoint inhibitors (CPI) a standard-of-care treatment for...
The role of conventional imaging and piflufolastat F18 in newly diagnosed and recurrent prostate cancer patients: Preliminary observations from the PYLARIFY Registry.
41 Background: Next generation imaging modalities for the diagnosis and characterization of prostate cancer have seen increased utilization in the past se...
Management of metastatic castration-resistant prostate cancer (mCRPC) at the Veterans Affairs Healthcare System (VAHCS): A real-world assessment of patient characteristics and treatment across lines of therapy.
60 Background: With the emergence of several newly approved therapies for mCRPC, data on the optimal treatment sequence are limited. The aim of this study...
THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.
TPS651 Background: Standard of care (SOC) for stage II seminoma involves primary orchidectomy with combination chemotherapy or external beam radiotherapy,...